Importance of in-hospital initiation of evidence-based medical therapies for heart failure - A review

American Journal of Cardiology

Volumn 94, Issue 9, 2004, Pages 1155-1160

  Fonarow, Gregg C ^a   Gheorghiade, Mihai ^b   Abraham, William T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A INHIBITOR; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METOPROLOL; NITRATE; PROPRANOLOL; SPIRONOLACTONE; TIMOLOL; UNCLASSIFIED DRUG;

BRADYCARDIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HEALTH PROGRAM; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; PATIENT EDUCATION; PERCEPTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT ADMISSION; RANDOMIZED CONTROLLED TRIALS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 7044247430     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.07.083     Document Type: Review

References (32)

1. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L Jessup ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 38 2001 2101 2113
2. M. Packer, J.N. Cohn Consensus recommendations for the management of chronic heart failure Am J Cardiol 83 1999 1A 38A
3. B. Pitt, G. Williams, W. Remme, F. Martinez, J. Lopez-Sendon, F. Zannad, J. Neaton, B. Roniker, S. Hurley, D Burns The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction Eplerenone Post-AMI Heart Failure Efficacy and Survival Study Cardiovasc Drugs Ther 15 2001 79 87
4. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
5. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure The SOLVD Investigators N Engl J Med 325 1991 293 302
6. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group N Engl J Med 316 1987 1429 1435
7. A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. El Allaf, J. Vitovec, J Aldershvile Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) MERIT-HF Study Group JAMA 283 2000 1295 1302
8. CIBIS-II Investigators The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
9. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, N.H. Shusterman The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
10. M. Packer, M.B. Fowler, E.B. Roecker, A.J. Coats, H.A. Katus, H. Krum, P. Mohacsi, J.L. Rouleau, M. Tendera, C Staiger Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Circulation 106 2002 2194 2199
11. G.C. Fonarow, K. Adams, B.P. Strausser ADHERE (Acute Decompensated Heart Failure National Registry): rationale, design, and subject population (abstr.) J Card Fail 8 2002 S49
12. G.C. Fonarow, C.W. Yancy, S.F. Chang Variation in heart failure quality of care indicators among U.S. hospitals: analysis of 230 hospitals in ADHERE Presented at the American Heart Association Scientific Session; Orlando, Florida; November 9-12, 2003 (abstract 2057) Circulation 108 suppl IV 2003 447
13. Yancy CW, Chang SF. Clinical characteristics and outcomes in patients admitted with heart failure with preserved systolic function: a report from the ADHERE database (poster 311). Presented at the 77th Annual Meeting of the Heart Failure Society of America; Las Vegas, Nevada; September 22, 2003.
14. R.S. Stafford, D.C. Radley The underutilization of cardiac medications of proven benefit, 1990 to 2002 J Am Coll Cardiol 41 2003 56 61
15. J.G. Cleland, A. Cohen-Solal, J.C. Aguilar, R. Dietz, J. Eastaugh, F. Follath, N. Freemantle, A. Gavazzi, W.H. van Gilst, F.D Hobbs Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey Lancet 360 2002 1631 1639
16. A.B. Luzier, L. DiTusa Underutilization of ACE inhibitors in heart failure Pharmacotherapy 19 1999 1296 1307
17. M. Ansari, M.G. Shilpak, P.A. Heindenreich, D. Van Ostaeyen, E.C. Pohl, W.S. Browner, B.M. Massie Improving guideline adherence. a randomized trial evaluating strategies to increase B-blocker use in heart failure Circulation 107 2003 2799 2804
18. G.C. Fonarow The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes Rev Cardiovasc Med 3 suppl 3 2002 S2 S10
19. D.J. Whellan, L. Gaulden, W.A. Gattis, B. Granger, S.D. Russell, M.A. Blazing, C.M. O'Conner The benefit of implementing a heart failure disease management program Arch Intern Med 161 2001 2223 2228
20. J. Butler, P.G. Arbogast, R. BeLue, J. Daughtery, M.K. Jain, W.A. Ray, M.R. Oriff Outpatient adherence to β-blocker therapy after acute myocardial infarction J Am Coll Cardiol 40 2002 1589 1595
21. G.C. Fonarow, A. Gawlinski Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles Am J Cardiol 85 2000 10A 17A
22. G.C. Fonarow, A. Gawlinski, S. Moughrabi, J.H. Tillisch Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) Am J Cardiol 87 2001 819 822
23. R.R. Pearson, B.D. Horne, C.A. Maycock, D.L. Lappe, S. Kralick-Goldberg, T.L. Bair, J.A. Orton, D.S. Wallace, B.B. Daniels, K. Rasmusson, S.P. Peyna An institutional heart failure medication program reduces future cardiovascular readmissions and mortality: an analysis of 19,083 heart failure patients (abstr) Circulation 104 suppl II 2001 838
24. G.C. Fonarow, L.W. Stevenson, J.A. Walden, N.A. Livingston, A.E. Steimle, M.A. Hamilton, J. Moriguchi, J.H. Tillisch, M.A. Woo Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure J Am Coll Cardiol 30 1997 725 732
25. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Pre-discharge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the IMPACT-HF (initiation management predischarge process for assessment of carvedilol therapy in heart failure) trial. J Am Coll Cardiol 2003;43:1534-1541.
26. Heart Failure Society of America Heart Failure Society of America (HFSA) practice guidelines HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches J Card Fail 5 1999 357 382
27. M. White, J.L. Rouleau, D. Pericak Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II) Eur Heart J 19 suppl 1998 308
28. H. Krum, E.B. Roecker, P. Mohacsi, J.L. Rouleau, M. Tendera, A.J. Coats, H.A. Katus, M.B. Fowler, M. Packer Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 2003 712 718
29. M. Packer, W.S. Colucci, J.D. Sackner-Bernstein, C.S. Liang, D.A. Goldscher, I. Freeman, M.L. Kukin, V. Kinhal, J.E. Udelson, M Klapholz Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise Circulation 94 1996 2793 2799
30. M.R. Bristow Mechanism of action of beta-blocking agents in heart failure Am J Cardiol 80 1997 26L 40L
31. S.S. Gottlieb, M.L. Fisher, J. Kjekshus, P. Deedwania, L. Gullestad, J. Vitovec, J. Wikstrand Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Circulation 105 2002 1182 1188
32. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.A. Gattis, M. Gheorghiade, B. Greenberg, C.M. O'Connor, C.W. Yancy, J. Young Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design Am Heart J 148 2004 43 51